S&P 500   3,280.13 (-1.07%)
DOW   27,072.80 (-0.79%)
QQQ   268.28 (-1.54%)
AAPL   109.02 (-2.50%)
MSFT   204.09 (-1.61%)
FB   253.08 (-0.66%)
GOOGL   1,428.45 (-2.15%)
AMZN   3,055.57 (-2.35%)
NVDA   498.94 (-1.30%)
TSLA   390.04 (-8.06%)
BABA   274.56 (-0.27%)
CGC   14.63 (-8.79%)
GE   6.22 (-0.48%)
MU   50.62 (+1.85%)
AMD   76.18 (-1.96%)
T   28.23 (-0.98%)
F   6.78 (+0.00%)
ACB   5.42 (-25.96%)
GILD   63.68 (+0.44%)
NFLX   480.14 (-2.25%)
DIS   124.96 (-1.77%)
BAC   23.82 (-0.50%)
BA   154.95 (-1.18%)
S&P 500   3,280.13 (-1.07%)
DOW   27,072.80 (-0.79%)
QQQ   268.28 (-1.54%)
AAPL   109.02 (-2.50%)
MSFT   204.09 (-1.61%)
FB   253.08 (-0.66%)
GOOGL   1,428.45 (-2.15%)
AMZN   3,055.57 (-2.35%)
NVDA   498.94 (-1.30%)
TSLA   390.04 (-8.06%)
BABA   274.56 (-0.27%)
CGC   14.63 (-8.79%)
GE   6.22 (-0.48%)
MU   50.62 (+1.85%)
AMD   76.18 (-1.96%)
T   28.23 (-0.98%)
F   6.78 (+0.00%)
ACB   5.42 (-25.96%)
GILD   63.68 (+0.44%)
NFLX   480.14 (-2.25%)
DIS   124.96 (-1.77%)
BAC   23.82 (-0.50%)
BA   154.95 (-1.18%)
S&P 500   3,280.13 (-1.07%)
DOW   27,072.80 (-0.79%)
QQQ   268.28 (-1.54%)
AAPL   109.02 (-2.50%)
MSFT   204.09 (-1.61%)
FB   253.08 (-0.66%)
GOOGL   1,428.45 (-2.15%)
AMZN   3,055.57 (-2.35%)
NVDA   498.94 (-1.30%)
TSLA   390.04 (-8.06%)
BABA   274.56 (-0.27%)
CGC   14.63 (-8.79%)
GE   6.22 (-0.48%)
MU   50.62 (+1.85%)
AMD   76.18 (-1.96%)
T   28.23 (-0.98%)
F   6.78 (+0.00%)
ACB   5.42 (-25.96%)
GILD   63.68 (+0.44%)
NFLX   480.14 (-2.25%)
DIS   124.96 (-1.77%)
BAC   23.82 (-0.50%)
BA   154.95 (-1.18%)
S&P 500   3,280.13 (-1.07%)
DOW   27,072.80 (-0.79%)
QQQ   268.28 (-1.54%)
AAPL   109.02 (-2.50%)
MSFT   204.09 (-1.61%)
FB   253.08 (-0.66%)
GOOGL   1,428.45 (-2.15%)
AMZN   3,055.57 (-2.35%)
NVDA   498.94 (-1.30%)
TSLA   390.04 (-8.06%)
BABA   274.56 (-0.27%)
CGC   14.63 (-8.79%)
GE   6.22 (-0.48%)
MU   50.62 (+1.85%)
AMD   76.18 (-1.96%)
T   28.23 (-0.98%)
F   6.78 (+0.00%)
ACB   5.42 (-25.96%)
GILD   63.68 (+0.44%)
NFLX   480.14 (-2.25%)
DIS   124.96 (-1.77%)
BAC   23.82 (-0.50%)
BA   154.95 (-1.18%)
Log in
NASDAQ:GILD

Gilead Sciences Stock Forecast, Price & News

$63.68
+0.28 (+0.44 %)
(As of 09/23/2020 01:39 PM ET)
Add
Compare
Today's Range
$63.40
Now: $63.68
$64.08
50-Day Range
$63.77
MA: $66.82
$71.73
52-Week Range
$60.89
Now: $63.68
$85.97
Volume251,575 shs
Average Volume15.37 million shs
Market Capitalization$79.84 billion
P/E RatioN/A
Dividend Yield4.24%
Beta0.56
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; and insitro Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Read More
Gilead Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 3.3Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.53 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GILD
CUSIP37555810
Phone650-574-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.45 billion
Cash Flow$7.01 per share
Book Value$17.90 per share

Profitability

Net Income$5.39 billion

Miscellaneous

Employees11,800
Outstanding Shares1,253,724,000
Market Cap$79.84 billion
Next Earnings Date10/22/2020 (Estimated)
OptionableOptionable
$63.68
+0.28 (+0.44 %)
(As of 09/23/2020 01:39 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

How has Gilead Sciences' stock been impacted by Coronavirus (COVID-19)?

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GILD stock has decreased by 13.4% and is now trading at $63.83.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Gilead Sciences?

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 2 sell ratings, 15 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Gilead Sciences
.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for Gilead Sciences
.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) posted its earnings results on Thursday, July, 30th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by $0.46. The biopharmaceutical company earned $5.14 billion during the quarter, compared to analysts' expectations of $5.24 billion. Gilead Sciences had a negative net margin of 1.16% and a positive return on equity of 33.59%.
View Gilead Sciences' earnings history
.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Thursday, July 30th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.68 per share on Tuesday, September 29th. This represents a $2.72 annualized dividend and a yield of 4.26%. The ex-dividend date is Monday, September 14th.
View Gilead Sciences' dividend history
.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences updated its FY20 earnings guidance on Thursday, July, 30th. The company provided earnings per share (EPS) guidance of $6.25-7.65 for the period, compared to the Thomson Reuters consensus estimate of $6.69. The company issued revenue guidance of $23.0-25.0 billion, compared to the consensus revenue estimate of $22.54 billion.

What price target have analysts set for GILD?

27 equities research analysts have issued 12 month price targets for Gilead Sciences' stock. Their forecasts range from $62.00 to $105.00. On average, they anticipate Gilead Sciences' stock price to reach $78.93 in the next twelve months. This suggests a possible upside of 23.7% from the stock's current price.
View analysts' price targets for Gilead Sciences
.

Has Gilead Sciences been receiving favorable news coverage?

News headlines about GILD stock have trended extremely negative recently, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Gilead Sciences earned a media sentiment score of -4.4 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Gilead Sciences
.

Are investors shorting Gilead Sciences?

Gilead Sciences saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 16,170,000 shares, a drop of 14.1% from the August 15th total of 18,830,000 shares. Based on an average daily trading volume, of 8,580,000 shares, the short-interest ratio is presently 1.9 days. Approximately 1.3% of the shares of the company are short sold.
View Gilead Sciences' Short Interest
.

Who are some of Gilead Sciences' key competitors?

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), Micron Technology (MU), Alibaba Group (BABA), Pfizer (PFE), Johnson & Johnson (JNJ), Netflix (NFLX), Tesla (TSLA) and AbbVie (ABBV).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the following people:
  • Ms. Robin L. Washington, CFO & Exec. VP (Age 56)
  • Dr. John G. McHutchison M.D., FRACP, Chief Scientific Officer and Head of R&D (Age 61)
  • Mr. Gregg H. Alton, Chief Patient Officer (Age 53)
  • Ms. Laura Hamill, Exec. VP of Worldwide Commercial Operations (Age 54)
  • Mr. Daniel O'Day, Chairman & CEO (Age 55)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.24%), Vanguard Group Inc. (8.36%), Bank of New York Mellon Corp (1.34%), FMR LLC (1.01%), California Public Employees Retirement System (0.84%) and Charles Schwab Investment Management Inc. (0.55%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John C Martin, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends for Gilead Sciences
.

Which major investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Federated Hermes Inc., Checchi Capital Advisers LLC, Vanguard Group Inc., Bank of New York Mellon Corp, Orbimed Advisors LLC, Banco Santander S.A., and AQR Capital Management LLC. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, Merdad Parsey, and Olsen Per Wold.
View insider buying and selling activity for Gilead Sciences
.

Which major investors are buying Gilead Sciences stock?

GILD stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., California Public Employees Retirement System, First Trust Advisors LP, APG Asset Management N.V., FMR LLC, Nordea Investment Management AB, Swiss National Bank, and Teacher Retirement System of Texas.
View insider buying and selling activity for Gilead Sciences
.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $63.83.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $80.03 billion and generates $22.45 billion in revenue each year. The biopharmaceutical company earns $5.39 billion in net income (profit) each year or $6.14 on an earnings per share basis. Gilead Sciences employs 11,800 workers across the globe.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is www.gilead.com.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.